Hemophagocytic Lymphohistiocytosis (HLH) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Hemophagocytic lymphohistiocytosis (HLH) is a condition in which the body makes too many activated immune cells (macrophages and lymphocytes). Etiology- There are inherited and non-inherited (acquired) causes of hemophagocytic lymphohistiocytosis (HLH). The acquired causes of HLH include infection, medications that suppress the immune system, autoimmune diseases, immunodeficiencies, certain types of cancer, and/or metabolic diseases. When HLH results from an inappropriate immune response to the Epstein-Barr virus or another viral illness, it may be due to a separate genetic condition called X-linked lymphoproliferative disease (XLP). XLP is caused by a mutation in the SH2D1A or XIAP gene and is inherited in an X-linked manner The competitive landscape of Hemophagocytic Lymphohistiocytosis (HLH) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst ...